Stockscreener 앱 받기
3.17
2.46%
-0.08
시간 외 거래:
3.24
0.07
+2.21%
전일 마감가:
$3.25
열려 있는:
$3.25
하루 거래량:
1.53M
Relative Volume:
1.21
시가총액:
$343.45M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-6.0962
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
-3.35%
1개월 성능:
+25.79%
6개월 성능:
+115.65%
1년 성능:
-1.55%
1일 변동 폭
$3.16
$3.385
1주일 범위
$3.12
$3.475
52주 변동 폭
$1.05
$3.475
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.17 | 352.12M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - setenews.com
Can Aclaris Therapeutics Inc. stock deliver sustainable ROE2025 Key Highlights & Consistent Return Investment Signals - Newser
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerTrade Risk Assessment & Weekly Stock Performance Updates - Newser
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How Aclaris Therapeutics Inc. (8AT) stock correlates with oil markets2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser
Can Comfort Intech Limited Maintain Profitability in a Rising Rate EnvironmentCandlestick Trading Patterns & Free Dynamic Profit Opportunities - earlytimes.in
Is Aclaris Therapeutics Inc. stock attractive for income investors2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Aclaris Therapeutics (ACRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aclaris Therapeutics engages investors at Piper Sandler Conference - Traders Union
Aclaris Therapeutics Inc (ACRS) is looking forward to a strong quarter - Setenews
Why Aclaris Therapeutics Inc. stock could rally in 2025Trade Analysis Report & Long-Term Capital Growth Ideas - BỘ NỘI VỤ
Can Aclaris Therapeutics Inc. stock beat analyst upgrades - moha.gov.vn
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - Markets Financial Content
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Top investors say Aclaris Therapeutics Inc (ACRS) ticks everything they need - setenews.com
Why Aclaris Therapeutics Inc. (8AT) stock attracts HNW investors - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock bottoming after sell offMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Yahoo Finance
How Aclaris Therapeutics Inc. stock benefits from tech adoptionNew Guidance & Smart Money Movement Alerts - newser.com
What hedge fund moves indicate for Aclaris Therapeutics Inc. (8AT) stockTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buyPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergers2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a buy for dividend portfoliosLayoff News & Fast Momentum Entry Tips - newser.com
How cyclical is Aclaris Therapeutics Inc. (8AT) stock compared to rivalsPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
What high frequency data says about Aclaris Therapeutics Inc.2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Rheumatoid Arthritis Market to Grow Significantly from ~20 Billion Over the Next Decade by 2034, DelveInsight Observes | R-Pharm, Taisho Pharmaceuticals, GSK, Aclaris, BMS, Eli Lilly, Taiho - Barchart.com
Aclaris Therapeutics at Jefferies Conference: Strategic Expansion in Biopharma By Investing.com - Investing.com Canada
Will Aclaris Therapeutics Inc. stock deliver shareholder value2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attention2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):